Key result
Tongxinluo capsules boost clinical efficacy to ~94% vs mecobalamin in diabetic peripheral neuropathy.
Why the study?
Do tongxinluo capsules improve clinical efficacy and nerve conduction velocity compared to mecobalamin in patients with diabetic peripheral neuropathy?
RCT (n=132)
Random even-odd number method
No
Do tongxinluo capsules improve clinical efficacy and nerve conduction velocity compared to mecobalamin in patients with diabetic peripheral neuropathy?
Tongxinluo capsules may improve clinical symptoms, blood glucose control, and nerve conduction velocity in patients with diabetic peripheral neuropathy compared to mecobalamin.
May support Tongxinluo capsules for diabetic peripheral neuropathy; confirms RCT efficacy and extends evidence on clinical response.
Objective: To observe the clinical effect of tongxinluo capsules in the treatment of diabetic peripheral neuropathy.Methods: A total of 132 patients with diabetic peripheral neuropathy in our hospital from June 2014 to June 2017 were selected as subjects.Using a random even-odd number method, the patients were divided into control (n=66) and treatment (n=66) groups.The patients in the control group were treated with mecobalamin, whereas the patients in the treatment group were treated with tongxinluo capsules.Clinical efficacy, blood glucose level change, electromyography nerve conduction velocity, and clinical signs of improvement were compared before and after treatment.Results: The total effective rate was significantly higher in the treatment group than in the control group (P<0.05).Meanwhile, the fasting blood glucose, postprandial 2 h blood glucose, and glycosylated hemoglobin levels were significantly lower in the treatment group than in the control group (P<0.05).Moreover, motor and sensory nerve conduction velocities were significantly higher in the treatment group than in the control group (P<0.05).The total effective rate of clinical symptom improvement was significantly lower in the treatment group than in the control group (P<0.05).Conclusion: Tongxinluo capsules can alleviate clinical symptoms, as well as improve therapeutic effects, blood glucose levels, and nerve conduction velocity, in patients with diabetic peripheral neuropathy.The capsules can be used as an ideal drug and merits popularization.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2018) conducted an RCT in Diabetic peripheral neuropathy (n=132). Tongxinluo capsules vs. Mecobalamin was evaluated on Total effective rate (clinical efficacy) (p=0.0194). Tongxinluo capsules significantly increased the total effective clinical rate to 93.9% compared to 80.3% with mecobalamin in patients with diabetic peripheral neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: